GlassScriptPhysician profile
Miso Gostimir
NPI 1598487597
$2,083.10
in general payments reported to CMS, 2019-2025
16 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $335 · 2023: $706 · 2024: $391 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $670.60 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $262.30 | 2023 | Lipiview Ocular Surface Interferometer, Lipiflow System Activator II (Disposable, Meibomian Gland Evaluator |
| Ucb, INC. | $219.33 | 2023-2024 | Rystiggo |
| E.R. Squibb & Sons, L.L.C. | $218.58 | 2022 | |
| Horizon Therapeutics Plc | $116.24 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $116.06 | 2022 | |
| Argenx US, INC. | $115.20 | 2023 | Vyvgart |
| Genzyme Corporation | $113.04 | 2024 | |
| Biogen, INC. | $79.67 | 2023 | |
| Harrow Eye, LLC | $32.53 | 2025 | Vevye |
| Emd Serono, INC. | $29.80 | 2024 | |
| Merz Pharmaceuticals, LLC | $28.21 | 2023 | Xeomin |
| Genentech USA, INC. | $23.71 | 2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $21.72 | 2025 | Eylea Hd |
| Biotissue Holdings INC. | $19.00 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $17.11 | 2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miso Gostimir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.